Articles liés à From Morphological Imaging to Molecular Targeting:...

From Morphological Imaging to Molecular Targeting: Implications for Preclinical Development - Couverture rigide

 
9783540201373: From Morphological Imaging to Molecular Targeting: Implications for Preclinical Development
Couverture rigide
ISBN 10 : 3540201378 ISBN 13 : 9783540201373
Editeur : Springer-Verlag Berlin and Heidelberg GmbH & Co. K, 2004

Synopsis

Because of the current progress in molecular medicine (genomics, proteomics), a plethora of new and often human-specific targets are being identified. These targets often play a significant role in the pathogenesis of diseases, and identifying them offers the potential for early diagnosis and intervention. An early in vivo validation of specific ligands binding to these targets in humans is needed to as­ sess their potential for targeted imaging and radiotherapy. Further- VI Preface more, such validation studies may allow for a better understanding of the molecular processes underlying phannacologic activity and therefore for a more successful development of phannaceuticals in general. The purpose of the Ernst Schering Research Foundation (ESRF) Workshop 48 was to provide a forum for an open exchange on the state of the art in the early development of such radiophanna­ ceuticals. Experts from academia, industry, and regulatory authori­ ties were invited to give presentations on aspects covering the identi­ fication of targets, preclinical studies on the safety of ligands, as well as their validation in human clinical trials. It was our intention to cover both the opportunities and the challenges that scientists in this field are facing. Radiopharmaceuticals are uniquely suitable for the above-men­ tioned target validation studies.

Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.

À propos de la quatrième de couverture

Because of the current progress in molecular medicine (genomics, proteomics), a plethora of new and often human-specific targets are being identified. These targets often play a significant role in the pathogenesis of diseases, and identifying them offers the potential for early diagnosis and intervention. An early in vivo validation of specific ligands binding to these targets in humans is needed to as­ sess their potential for targeted imaging and radiotherapy. Further- VI Preface more, such validation studies may allow for a better understanding of the molecular processes underlying phannacologic activity and therefore for a more successful development of phannaceuticals in general. The purpose of the Ernst Schering Research Foundation (ESRF) Workshop 48 was to provide a forum for an open exchange on the state of the art in the early development of such radiophanna­ ceuticals. Experts from academia, industry, and regulatory authori­ ties were invited to give presentations on aspects covering the identi­ fication of targets, preclinical studies on the safety of ligands, as well as their validation in human clinical trials. It was our intention to cover both the opportunities and the challenges that scientists in this field are facing. Radiopharmaceuticals are uniquely suitable for the above-men­ tioned target validation studies.

Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.

Éditeur
Springer-Verlag Berlin and Heidelberg GmbH & Co. K
Date d'édition
2004
Langue
anglais
ISBN 10 
3540201378
ISBN 13 
9783540201373
Reliure
Relié
Nombre de pages
191
Éditeur
Schwaiger Markus, Dinkelborg L., Schweinfurth H.
Coordonnées du fabricant
ProductSafety@springernature.com
ProductSafety@springernature.com

Europaplatz 3
Heidelberg
69115
Allemagne